Angelini Group - Product Pipeline Review – 2015 Is Released

This report provides comprehensive information on the current therapeutic developmental pipeline of Angelini Groups, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Angelini Group including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Angelini Groups human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Angelini Groups pipeline products Reasons to buy - Evaluate Angelini Groups strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Angelini Group in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Angelini Groups R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Angelini Group and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angelini Group - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Angelini Group and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179134/angelini-group-product-pipeline-review-2015
To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179134/angelini-group-product-pipeline-review-2015
Table of Contents
Table of Contents 2

List of Tables 4

List of Figures 4

Angelini Group Snapshot 5

Angelini Group Overview 5

Key Information 5

Key Facts 5

Angelini Group - Research and Development Overview 6

Key Therapeutic Areas 6

Angelini Group - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Angelini Group - Pipeline Products Glance 12

Angelini Group - Late Stage Pipeline Products 12

Pre-Registration Products/Combination Treatment Modalities 12

Phase III Products/Combination Treatment Modalities 13

Angelini Group - Early Stage Pipeline Products 14

Discovery Products/Combination Treatment Modalities 14

Angelini Group - Drug Profiles 15

trazodone hydrochloride 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

prulifloxacin 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Drug to Inhibit NAMPT for Pain and Inflammation 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Drug to Inhibit Prokineticin Receptor 1 for Pain and Inflammation 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Drugs to Inhibit Beta Lactamase for Bacterial Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecules to Inhibit Gyrase and Topoisomerase IV for Infectious Diseases 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Angelini Group - Pipeline Analysis 23

Angelini Group - Pipeline Products by Target 23

Angelini Group - Pipeline Products by Route of Administration 24

Angelini Group - Pipeline Products by Molecule Type 25

Angelini Group - Pipeline Products by Mechanism of Action 26

Angelini Group - Recent Pipeline Updates 27

Angelini Group - Dormant Projects 28

Angelini Group - Company Statement 29

Angelini Group - Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Angelini Group Snapshot 5

Angelini Group Overview 5

Key Information 5

Key Facts 5

Angelini Group - Research and Development Overview 6

Key Therapeutic Areas 6

Angelini Group - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Angelini Group - Pipeline Products Glance 12

Angelini Group - Late Stage Pipeline Products 12

Pre-Registration Products/Combination Treatment Modalities 12

Phase III Products/Combination Treatment Modalities 13

Angelini Group - Early Stage Pipeline Products 14

Discovery Products/Combination Treatment Modalities 14

Angelini Group - Drug Profiles 15

trazodone hydrochloride 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

prulifloxacin 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Drug to Inhibit NAMPT for Pain and Inflammation 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Drug to Inhibit Prokineticin Receptor 1 for Pain and Inflammation 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Drugs to Inhibit Beta Lactamase for Bacterial Infections 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecules to Inhibit Gyrase and Topoisomerase IV for Infectious Diseases 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Angelini Group - Pipeline Analysis 23

Angelini Group - Pipeline Products by Target 23

Angelini Group - Pipeline Products by Route of Administration 24

Angelini Group - Pipeline Products by Molecule Type 25

Angelini Group - Pipeline Products by Mechanism of Action 26

Angelini Group - Recent Pipeline Updates 27

Angelini Group - Dormant Projects 28

Angelini Group - Company Statement 29

Angelini Group - Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

Read More http://www.idatainsights.com/reports-landing-page.php?id=179134/angelini-group-product-pipeline-review-2015

About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com

About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.